Avidity Biosciences, Inc

Avidity Biosciences — Technical Presentation (August 2024)

25 slides from Avidity Biosciences's technical presentation, Aug 9, 2024

  1. Slide 1: Transforming Duchenne Muscular Dystrophy (DMD): AOC 1044 EXPLORE44 Phase 1/2 Initial Data

    1 August 9, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 10 Transforming Duchenne Muscular Dystrophy (DMD) AOC 1044 EXPLORE44TM Phase 1/2 Initial Data

  2. Slide 2: Forward-looking statements

    2 We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking statements include, but are not

  3. Slide 3: Our Vision

    3 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Nathan, living with DMD, and his father, Brad

  4. Slide 4: Purpose of Update

    4 Purpose of Update Present initial data from Phase 1/2 EXPLORE44 Del-zota 5mg/kg at 4-month timepoint • Unsurpassed delivery to muscle • Statistically significant robust exon skipping • Statistically significant dystrophin production • Profound reduction in creatine kinase • Favorable safety and to

  5. Slide 5: Del-zota: Potential New Treatment for People Living with DMD44

    5 Del-zota: Potential New Treatment for People Living with DMD44 Unsurpassed Delivery to Muscle • Consistent delivery of PMO of 200 nM in skeletal muscle Significant Exon Skipping • Robust 37% increase in exon skipping • Up to 66% increase in exon skipping Significant Dystrophin Production • Substan

  6. Slide 6: Avidity Management Team

    6 Steve Hughes, M.D. Chief Medical Officer Sarah Boyce President & CEO W. Michael Flanagan, Ph.D. Chief Scientific & Technical Officer Michael MacLean Chief Financial & Business Officer Transforming the Treatment of DMD AVIDITY MANAGEMENT TEAM

  7. Slide 7: Transforming the Treatment of DMD44

    Transforming the Treatment of DMD44

  8. Slide 8: DMD: Hereditary Disorder Causing Progressive, Debilitating Muscle Damage

    8 DMD: Hereditary Disorder Causing Progressive, Debilitating Muscle Damage and Significantly Reduced Life Expectancy • Monogenic, X-linked, recessive condition characterized by progressive muscle damage and weakness • Primarily affects males, loss of ambulation by teenage years • Significantly reduc

  9. Slide 9: EXPLORE44 Phase 1/2 DMD44 Cohorts: Overview & Objectives

    9 EXPLORE44 Phase 1/2 DMD44 Cohorts: Overview & Objectives • Measures of muscle function • Patient-reported outcomes (PRO) • Quality of life Key Exploratory ObjectivesKey Information • Pharmacokinetics • Pharmacodynamics • Exon 44 skipping • Dystrophin protein levels Secondary ObjectivesPrimary Obje

  10. Slide 10: Demographics and Baseline Characteristics

    10 Demographics and Baseline Characteristics Placebo N=3 mean (SD) Del-Zota 5.0 mg/kg N=9 mean (SD) Age (yrs) 13.7 (2.5) 16.0 (4.7) BMI (kg/m2) 23.1 (5.5) 24.2 (5.6) Age of Symptom Onset (yrs) 3.8 (2.9) 3.6 (2.3) Creatine Kinase, U/L 7,118 (1659) 5,033 (3246) Corticosteroid Use 100% 100%

  11. Slide 11: Del-zota: Favorable Safety and Tolerability in DMD44 Patients

    11 Del-zota: Favorable Safety and Tolerability in DMD44 Patients Subjects with ≥ 1 TEAE n (%) Placebo N=7 5.0 mg/kg N=9 10 mg/kg N=9 Any AE 4 (57%) 8 (89%) 4 (44%) Related to study drug 0 2 (22%) 1 (11%) Serious AE (SAE) 0 1 (11%) 0 AE leading to study discontinuation 0 2 (22%) 0 AE leading to death

  12. Slide 12: Expediting Del-zota Registrational Plan

    12 Expediting Del-zota Registrational Plan 3: 1 Ra nd om iz at io n AO C 10 44 : P la ce bo A Healthy Volunteer Cohorts B1 B2 5.0 mg/kg 10.0 mg/kg Dose – dose listed is PMO Initiation of next dose level cohort Part A: Healthy Volunteers Part B: Participants with DMD amenable to exon 44 skipping 7.5-

  13. Slide 13: Del-zota: Initial Data from 5mg/kg Cohort

    Del-zota: Initial Data from 5mg/kg Cohort

  14. Slide 14: Del-zota: Transforming the Treatment of DMD44

    14 Del-zota: Transforming the Treatment of DMD44 Unsurpassed Delivery to Muscle Statistically Significant Robust Exon Skipping Statistically Significant Dystrophin Production Profound Decrease in Creatine Kinase Biomarker • Consistent delivery of PMO of 200 nM in skeletal muscle • Once again, reinfo

  15. Slide 15: Del-zota Produces Near Full-Length Dystrophin

    15 Del-zota Produces Near Full-Length Dystrophin Naturally occurring dystrophin Representative dystrophin produced by del-zota Micro-dystrophin produced by gene therapies N H1 R1 R2 R3 H2 R 24 H4 CR N H1 R1 R2 R3 H2 R4 R5 R6 R7 R8 R9 R 10 R 11 R 12 R 13 R 14 R 15 R 16 R 17 R 18 R 19 H3 R 20 R 21 R 2

  16. Slide 16: Del-zota: Unsurpassed Delivery to Muscle in DMD Participants

    16 Del-zota: Unsurpassed Delivery to Muscle in DMD Participants Single Dose Q6W X 3 0 50 100 150 200 PM O 44 (n M ) DMD44 HV Del-Zota (5 mg/kg) D D exon44 HV HV DMD44 del-zota (5 mg/kg) PMO44 muscle tissue concentrations were determined utilizing HPLC. Muscle biopsy collected from vastus lateralis (

  17. Slide 17: Del-zota: Increase of 37% in Exon Skipping

    17 Del-zota: Increase of 37% in Exon 44 Skipping Statistically significant increase in exon 44 skipping of up to 66% Muscle biopsy collected from biceps brachii at 1 month post last dose (q6W x 3). Mean +/- SEM. N=3 placebo and N=7 del-zota. Exon 44 skipping determined using ddPCR. *p<0.05 by Wilcox

  18. Slide 18: Del-zota: Increase of 25% of Normal in Dystrophin Production

    18 Del-zota: Increase of 25% of Normal in Dystrophin Production Significantly restored total dystrophin up to 54% of normal Dystrophin protein determined in biceps brachii muscle biopsy at 1 month post 3rd dose by Western Blot. Data normalized to myosin heavy chain. Mean +/- SEM. N=3 (Placebo), N=7

  19. Slide 19: Del-zota: Creatine Kinase Levels Decrease to Near Normal

    19 Del-zota: Creatine Kinase Levels Decrease to Near Normal Creatine kinase reduced by greater than 80% compared to baseline Upper limit of normal (ULN) 0 10 20 30 40 50 60 70 80 90 100 110 120 0 2000 4000 6000 8000 10000 12000 14000 Study Day C re at in e K in as e (U /L ) m ea n (S EM ) PBO (N=3)

  20. Slide 20: Del-zota: First of Multiple AOCs in DMD Franchise

    20 Del-zota: First of Multiple AOCs in DMD Franchise Data support expediting advancement of additional exon-skipping candidates Unsurpassed Delivery to Muscle Statistically Significant Robust Exon Skipping Statistically Significant Dystrophin Production Profound Decrease in Creatine Kinase Biomarker

  21. Slide 21: Revolutionizing the Delivery of RNA Therapeutics

    Revolutionizing the Delivery of RNA Therapeutics

  22. Slide 22: Avidity is Committed to Partnering with the DMD Community

    22 Avidity is Committed to Partnering with the DMD Community to Efficiently Advance Treatment Options • FDA has granted del-zota Orphan Drug, Fast Track and Rare Pediatric Disease designations. EMA has granted del-zota Orphan designation • EXPLORE44 enrollment complete; plan to enroll additional pat

  23. Slide 23: Our Vision

    23 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Lee, living with DMD, and his family

  24. Slide 24: Q&A

    24 August 9, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 10 Transforming Duchenne Muscular Dystrophy (DMD) AOC 1044 EXPLORE44TM Phase 1/2 Initial Data Q&A

  25. Slide 25: Transforming Duchenne Muscular Dystrophy (DMD): AOC 1044 EXPLORE44 Phase 1/2 Initial Data

    25 August 9, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 10 Transforming Duchenne Muscular Dystrophy (DMD) AOC 1044 EXPLORE44TM Phase 1/2 Initial Data

Avidity Biosciences — Technical Presentation (August 2024) on 6ix